0001104659-12-052481.txt : 20120731 0001104659-12-052481.hdr.sgml : 20120731 20120731083646 ACCESSION NUMBER: 0001104659-12-052481 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120731 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120731 DATE AS OF CHANGE: 20120731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERISOURCEBERGEN CORP CENTRAL INDEX KEY: 0001140859 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 233079390 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16671 FILM NUMBER: 12995356 BUSINESS ADDRESS: STREET 1: 1300 MORRIS DRIVE CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 BUSINESS PHONE: 6107277000 MAIL ADDRESS: STREET 1: 1300 MORRIS DRIVE CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 8-K 1 a12-17324_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported): July 31, 2012

 

AmerisourceBergen Corporation

(Exact name of Registrant as specified in its charter)

 

Delaware

 

1-16671

 

23-3079390

(State or Other

 

Commission File Number

 

(I.R.S. Employer

Jurisdiction of

 

 

 

Identification

Incorporation or

 

 

 

Number)

Organization)

 

 

 

 

 

 

1300 Morris Drive

 

 

Chesterbrook, PA

 

19087

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (610) 727-7000

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01.                Other Events.

 

In connection with AmerisourceBergen Corporation’s (the “Registrant’s”) acquisition of World Courier Group, Inc. (“World Courier”) during the quarter ended June 30, 2012, the Registrant concluded that World Courier, a separate operating segment, does not meet the criteria to be aggregated with the AmerisourceBergen Drug Corporation (“ABDC”), AmerisourceBergen Specialty Group (“ABSG”), and AmerisourceBergen Consulting Services (“ABCS”) operating segments due to the nature of World Courier’s operations and its different revenue growth rates and operating income margins.  As a result and beginning with the June 30, 2012 quarterly reporting period, the Registrant will report the results of its ABDC and ABSG operating segments in the Pharmaceutical Distribution reportable segment.  The results of operations of the World Courier and ABCS operating segments are not significant enough to require separate reportable segment disclosure, and therefore will be included in “Other” for the purpose of reportable segment presentation.

 

Attached as Exhibit 99.1 and incorporated by reference into this report, the Registrant has provided unaudited segment financial information for the first three quarters of its 2012 and 2011 fiscal years.  In future filings with the Securities and Exchange Commission, the Registrant will include the results of its Pharmaceutical Distribution and Other reportable segments.

 

Item 9.01.                Financial Statements and Exhibits.

 

(d)                                 Exhibits.

 

99.1                        Unaudited segment financial information for the fiscal year 2012 quarters ending December 31, 2011, March 31, 2012, and June 30, 2012.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

AMERISOURCEBERGEN CORPORATION

 

 

 

Date: July 31, 2012

By:

/s/ Tim G. Guttman

 

Name:

Tim G. Guttman

 

Title:

Senior Vice President and Chief Financial Officer

 

3

 EX-99.1 2 a12-17324_1ex99d1.htm EX-99.1

Exhibit 99.1

 

AmerisourceBergen Corporation

Unaudited Summary Segment Information

(dollars in thousands)

 

 

 

Three Months Ended December 31,

 

 

 

Three Months Ended March 31,

 

 

 

Three Months Ended June 30,

 

 

 

Revenue

 

2011

 

2010

 

Change

 

2012

 

2011

 

Change

 

2012

 

2011

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical Distribution

 

$

20,134,050

 

$

19,778,084

 

2%

 

$

19,757,210

 

$

19,652,364

 

1%

 

$

19,372,722

 

$

20,036,062

 

(3)%

 

Other

 

258,061

 

120,398

 

114%

 

357,696

 

122,520

 

192%

 

453,701

 

140,100

 

224%

 

Intersegment eliminations

 

(31,466

)

(9,873

)

219%

 

(43,635

)

(14,627

)

198%

 

(57,039

)

(15,140

)

277%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

20,360,645

 

$

19,888,609

 

2%

 

$

20,071,271

 

$

19,760,257

 

2%

 

$

19,769,384

 

$

20,161,022

 

(2)%

 

 

 

 

Three Months Ended December 31,

 

 

 

Three Months Ended March 31,

 

 

 

Three Months Ended June 30,

 

 

 

Operating Income

 

2011

 

2010

 

Change

 

2012

 

2011

 

Change

 

2012

 

2011

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical Distribution

 

$

276,385

 

$

268,148

 

3%

 

$

350,021

 

$

346,894

 

1%

 

$

295,296

 

$

304,877

 

(3)%

 

Other

 

12,088

 

8,618

 

40%

 

27,107

 

18,355

 

48%

 

23,243

 

12,282

 

89%

 

Employee severance, litigation and other

 

(3,559

)

—

 

N/M

 

(9,027

)

—

 

N/M

 

(4,844

)

—

 

N/M

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

$

284,914

 

$

276,766

 

3%

 

$

368,101

 

$

365,249

 

1%

 

$

313,695

 

$

317,159

 

(1)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Percentages of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical Distribution

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

2.74%

 

2.78%

 

 

 

3.22%

 

3.30%

 

 

 

3.06%

 

3.08%

 

 

 

Operating expenses

 

1.37%

 

1.43%

 

 

 

1.44%

 

1.53%

 

 

 

1.53%

 

1.56%

 

 

 

Operating income

 

1.37%

 

1.36%

 

 

 

1.77%

 

1.77%

 

 

 

1.52%

 

1.52%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

15.67%

 

24.49%

 

 

 

16.70%

 

32.42%

 

 

 

21.30%

 

25.65%

 

 

 

Operating expenses

 

10.98%

 

17.34%

 

 

 

9.12%

 

17.44%

 

 

 

16.18%

 

16.88%

 

 

 

Operating income

 

4.68%

 

7.16%

 

 

 

7.58%

 

14.98%

 

 

 

5.12%

 

8.77%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmerisourceBergen Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

2.91%

 

2.92%

 

 

 

3.46%

 

3.48%

 

 

 

3.49%

 

3.24%

 

 

 

Operating expenses

 

1.51%

 

1.53%

 

 

 

1.63%

 

1.63%

 

 

 

1.90%

 

1.67%

 

 

 

Operating income

 

1.40%

 

1.39%

 

 

 

1.83%

 

1.85%

 

 

 

1.59%

 

1.57%